Effects of oral appliances and CPAP on the left ventricle and natriuretic peptides

International Journal of Cardiology

Volumn 128, Issue 2, 2008, Pages 232-239

  Hoekema, Aarnoud ^a   Voors, Adriaan A ^a   Wijkstra, Peter J ^a   Stegenga, Boudewijn ^a   van der Hoeven, Johannes H ^a   Tol, Cornelis G ^b   de Bont, Lambert G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MARTINI HOSPITAL   (Netherlands)

Author keywords

Cardiovascular disease; CPAP; Oral appliance; Sleep apnea syndrome

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; BLOOD ANALYSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYSOMNOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLEEP APNEA SYNDROME;

CARDIOVASCULAR DISEASES; CONTINUOUS POSITIVE AIRWAY PRESSURE; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MANDIBULAR ADVANCEMENT; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; ORTHODONTIC APPLIANCES, REMOVABLE; PEPTIDE FRAGMENTS; POLYSOMNOGRAPHY; SLEEP APNEA, OBSTRUCTIVE; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 47749092767     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.06.016     Document Type: Article

References (42)

1. Malhotra A., and White D.P. Obstructive sleep apnoea. Lancet 360 (2005) 237-245
2. Kaneko Y., Floras J.S., Usui K., et al. Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. N Engl J Med 348 (2003) 1233-1241
3. Wolk R., Kara T., and Somers V.K. Sleep-disordered breathing and cardiovascular disease. Circulation 108 (2003) 9-12
4. Marin J.M., Carrizo S.J., Vicente E., and Agusti A.G. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365 (2005) 1046-1053
5. Laaban J.P., Cassuto D., Orvoen-Frija E., et al. Cardiorespiratory consequences of sleep apnoea syndrome in patients with massive obesity. Eur Respir J 11 (1998) 20-27
6. Laaban J.P., Pascal-Sebaoun S., Bloch E., Orvoen-Frija E., Oppert J.M., and Huchon G. Left ventricular systolic dysfunction in patients with obstructive sleep apnea syndrome. Chest 122 (2002) 1133-1138
7. Alchanatis M., Tourkohoriti G., Kosmas E.N., et al. Evidence for left ventricular dysfunction in patients with obstructive sleep apnoea syndrome. Eur Respir J 20 (2002) 1239-1245
8. Cloward T.V., Walker J.M., Farney R.J., and Anderson J.L. Left ventricular hypertrophy is a common echocardiographic abnormality in severe obstructive sleep apnea and reverses with nasal continuous positive airway pressure. Chest 124 (2003) 594-601
9. Arias M.A., Garcia-Rio F., Alonso-Fernandez A., Mediano O., Martinez I., and Villamor J. Obstructive sleep apnea syndrome affects left ventricular diastolic function: effects of nasal continuous positive airway pressure in men. Circulation 112 (2005) 375-383
10. Dursunoglu D., Dursunoglu N., Evrengul H., et al. Impact of obstructive sleep apnoea on left ventricular mass and global function. Eur Respir J 26 (2005) 283-288
11. Pepperell J.C., Ramdassingh-Dow S., Crosthwaite N., et al. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet 359 (2002) 204-210
12. Peled N., Abinader E.G., Pillar G., Sharif D., and Lavie P. Nocturnal ischemic events in patients with obstructive sleep apnea syndrome and ischemic heart disease: effects of continuous positive air pressure treatment. J Am Coll Cardiol 34 (1999) 1744-1749
13. Kragelund C., Gronning B., Kober L., Hildebrandt P., and Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 352 (2005) 666-675
14. Kita H., Ohi M., Chin K., et al. The nocturnal secretion of cardiac natriuretic peptides during obstructive sleep apnoea and its response to therapy with nasal continuous positive airway pressure. J Sleep Res 7 (1998) 199-207
15. Barnes M., Houston D., Worsnop C.J., et al. A randomized controlled trial of continuous positive airway pressure in mild obstructive sleep apnea. Am J Respir Crit Care Med 165 (2002) 773-780
16. Hoekema A., Stegenga B., and De Bont L.G. Efficacy and co-morbidity of oral appliances in the treatment of obstructive sleep apnea-hypopnea: a systematic review. Crit Rev Oral Biol Med 15 (2004) 137-155
17. Barnes M., McEvoy R.D., Banks S., et al. Efficacy of positive airway pressure and oral appliance in mild to moderate obstructive sleep apnea. Am J Respir Crit Care Med 170 (2004) 656-664
18. Gotsopoulos H., Kelly J.J., and Cistulli P.A. Oral appliance therapy reduces blood pressure in obstructive sleep apnea: a randomized, controlled trial. Sleep 27 (2004) 934-941
19. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The report of an American Academy of Sleep Medicine task force. Sleep 22 (1999) 667-689
20. Petit F.X., Pepin J.L., Bettega G., Sadek H., Raphael B., and Levy P. Mandibular advancement devices: rate of contraindications in 100 consecutive obstructive sleep apnea patients. Am J Respir Crit Care Med 166 (2002) 274-278
21. Altman D.G. Designing research. In: Altman D.G. (Ed). Practical Statistics for Medical Research. 1st edition (1991), Chapman & Hall, London/England 74-106
22. Johns M.W. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14 (1991) 540-545
23. Hoekema A., Stegenga B., van der Aa J.G., Meinesz A.F., van der Hoeven J.H., and Wijkstra P.J. Nap-titration: an effective alternative for continuous positive airway pressure titration. Respir Med 100 (2006) 705-713
24. EEG arousals: scoring rules and examples: a preliminary report from the Sleep Disorders Atlas task force of the American Sleep Disorders Association. Sleep 15 (1992) 173-184
25. Rechtschaffen A., and Kales A.A. Manual of standardized terminology, techniques and scoring system for the sleep stages of human subjects. NIH Publication No. 204 (1968), U.S. Government Printing Office, Washington, DC 1-1-0068
26. Recording and scoring leg movements. The Atlas task force. Sleep 16 (1993) 748-759
27. Devereux R.B., and Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 55 (1977) 613-618
28. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography committee on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
29. Hammond I.W., Devereux R.B., Alderman M.H., et al. The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol 7 (1986) 639-650
30. In: Weyman A.E. (Ed). Principles and practice of echocardiography. 2nd edition (1994), Lea & Febiger, Philadelphia 1289-1298
31. In: Feigenbaum H. (Ed). Echocardiography. 5th edition (1993), Williams & Wilkins, Baltimore 658-683
32. Galasko G.I., Lahiri A., Barnes S.C., Collinson P., and Senior R. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease?. Eur Heart J 26 (2005) 2269-2276
33. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice. Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Arch Mal Coeur Vaiss 97 (2004) 1019-1030
34. Mosterd A., D'Agostino R.B., Silbershatz H., et al. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med 340 (1999) 1221-1227
35. Tingleff J., Munch M., Jakobsen T.J., et al. Prevalence of left ventricular hypertrophy in a hypertensive population. Eur Heart J 17 (1996) 143-149
36. Schirmer H., Lunde P., and Rasmussen K. Prevalence of left ventricular hypertrophy in a general population; the Tromso Study. Eur Heart J 20 (1999) 429-438
37. Lauer M.S., Evans J.C., and Levy D. Prognostic implications of subclinical left ventricular dilatation and systolic dysfunction in men free of overt cardiovascular disease (the Framingham Heart Study). Am J Cardiol 70 (1992) 1180-1184
38. Vasan R.S., Larson M.G., Benjamin E.J., Evans J.C., and Levy D. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med 336 (1997) 1350-1355
39. Williams S.G., Ng L.L., O'Brien R.J., Taylor S., Li Y.F., and Tan L.B. Comparison of plasma N-brain natriuretic peptide, peak oxygen consumption, and left ventricular ejection fraction for severity of chronic heart failure. Am J Cardiol 93 (2004) 1560-1564
40. Troughton R.W., Prior D.L., Pereira J.J., et al. Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol 43 (2004) 416-422
41. Eskafi M. Sleep apnoea in patients with stable congestive heart failure an intervention study with a mandibular advancement device. Swed Dent J Suppl (2004) 1-56
42. Demirozu M.C., Chediak A.D., Nay K.N., and Cohn M.A. A comparison of nine nasal continuous positive airway pressure machines in maintaining mask pressure during simulated inspiration. Sleep 14 (1991) 259-262